Douglas Adkins

Medicine & Life Sciences

1. Squamous Cell Carcinoma of Head and Neck 100%
2. Cetuximab 65%
3. Head and Neck Neoplasms 51%
4. Survival 37%
5. Squamous Cell Carcinoma 35%
6. Peripheral Blood Stem Cells 31%
7. Stem Cell Transplantation 31%
8. Transplants 30%
9. Neoplasms 29%
10. Bone Marrow Transplantation 26%
11. 130-nm albumin-bound paclitaxel 26%
12. Granulocyte Colony-Stimulating Factor 25%
13. Drug Therapy 25%
14. Oropharyngeal Neoplasms 25%
15. Sarcoma 25%
16. Therapeutics 24%
17. Graft vs Host Disease 24%
18. Radiotherapy 23%
19. Peripheral Blood Stem Cell Transplantation 23%
20. Cisplatin 22%
21. Autologous Transplantation 22%
22. palbociclib 22%
23. Induction Chemotherapy 22%
24. Progression-Free Survival 21%
25. Whole-Body Irradiation 20%
26. Bone Marrow 19%
27. Recurrence 18%
28. Unrelated Donors 17%
29. Docetaxel 17%
30. Tissue Donors 17%
31. pembrolizumab 17%
32. Stem Cells 17%
33. Homologous Transplantation 16%
34. Radiation 16%
35. Neutrophils 16%
36. Transplant Recipients 16%
37. Granulocytes 15%
38. Neck 13%
39. Cyclophosphamide 13%
40. Neoplasm Metastasis 13%
41. Safety 12%
42. dusquetide 12%
43. Breast Neoplasms 12%
44. Bone Neoplasms 12%
45. Platinum 11%
46. Albumin-Bound Paclitaxel 11%
47. temsirolimus 10%
48. Allogeneic Cells 10%
49. Mouth 10%
50. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10%